Ompranyt (Omeprazole)

Omeprazole, the active ingredient in Ompranyt, is a Proton Pump Inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal disorders in adults and children when appropriate. GNH USA supplies Ompranyt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ompranyt belongs to the proton pump inhibitor class and is used to treat conditions driven by excess gastric acid. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal irritation. - Peptic ulcer disease: enhances ulcer healing and lowers the risk of recurrence. - Zollinger‑Ellison syndrome: controls pathological hypersecretion of gastric acid. - Erosive esophagitis: reduces inflammation and supports mucosal repair. - Helicobacter pylori eradication regimens (adjunct): improves antibiotic efficacy by maintaining a less acidic gastric environment.

Ompranyt is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Diarrhea - Abdominal pain - Nausea

Serious or Rare Side Effects: - Clostridioides difficile infection - Severe allergic reaction (anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Ompranyt, clinicians should consider several safety aspects. - Assess renal function: adjust use in patients with severe renal impairment. - Evaluate for Helicobacter pylori infection: testing before long‑term therapy is advisable. - Monitor bone health: prolonged use may affect calcium absorption and increase fracture risk. - Avoid concomitant use with certain antiplatelet agents: may heighten bleeding tendency. - Store at room temperature: keep in the original container, protect from moisture and light.

Ompranyt can alter the pharmacokinetics of several medicines, requiring careful management.

Major Interactions (Avoid): - Rilpivirine: reduced antiviral exposure. - Atazanavir: decreased antiretroviral levels. - Clopidogrel: possible reduction in antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR. - Digoxin: may raise serum concentrations. - Methotrexate: risk of heightened toxicity.